Jeffrey Crawford | Scholars@Duke

Jeffrey Crawford
George Barth Geller Professor

1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care

Accomplishments

1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.

Current Appointments & Affiliations

George Barth Geller Professor, Medicine, Medical Oncology, Medicine 2005
Professor of Medicine, Medicine, Medical Oncology, Medicine 1997
Associate Director of Clinical Research, Comprehensive Cancer Center, Duke Cancer Institute, Institutes and Centers 1995
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1974

Contact Information

443 Seeley G. Mudd Bldg, Durham, NC 27710
Duke Box 3476, Durham, NC 27710
crawf006@mc.duke.edu (919) 681-9509

Background
Education, Training, & Certifications
- M.D., Ohio State University 1974
Duke Appointment History
- Chief of the Medical Oncology and Transplantation Division in the Department of Medicine, Medicine, Medical Oncology, Medicine 2003 - 2013
- Acting Director for Clinical Services for the Division of Medical Oncology in the Department of Medicine, Medicine, Clinical Science Departments 1998 - 2003
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 1992 - 1997
- Associate in the Department of Medicine, Medicine, Clinical Science Departments 1978 - 1982
Research
Selected Grants
- BR.31 awarded by Clinipace, Inc. 2016 - 2026
- Phase II anetumab ravtansine as 2nd line treatment for malignant pleural mesothelioma awarded by Bayer HealthCare AG 2016 - 2021
- A phase II, Open-label, single-arm study to assess the safety and efficacy of AZD9291 in patients with locally advanced/ awarded by AstraZeneca AB 2014 - 2019
- NCI National Clinical Trials Network U10 (Year 4) awarded by National Institutes of Health 2014 - 2019
- Identification of Genetic Determinates for Disparities in African American Patients with Non-Small Cell Lung Cancer awarded by V Foundation for Cancer Research 2016 - 2017
- TIGER 1: A randomized, open-label, phase II study of CO-1686 or Erlotinib as first-line treatment of patients with EGFR-Mutant advanced non-small cell lung cancer awarded by Clovis Oncology, Inc. 2015 - 2017
- A phase 2, randomized, double-blind study comparing Tremelimumab to placebo in Second- or third-line treatment of subjec awarded by MedImmune, Inc. 2013 - 2017
- A phase III, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of selumetinib (AZD624 awarded by AstraZeneca Pharmaceuticals, LP 2014 - 2016
- FibroGen, Inc. FGCL-3019-073 awarded by Fibrogen, Inc. 2015 - 2016
- MORAb-009-021 awarded by Morphotek, Inc 2016
- A Decision Aid with HRQL Assessment to Reduce Costs in the Treatment of NSCLC awarded by University of Virginia - Charlottesville 2012 - 2015
- Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
- ANC Study Group awarded by Fred Hutchinson Cancer Research Center 2014
- Cancer and Leukemia Group B awarded by National Institutes of Health 2009 - 2014
- Research Training in Cancer Biology and Therapy awarded by National Institutes of Health 1978 - 2013
- Refining and Validating Genomic Signatures in Lung Cancer awarded by National Institutes of Health 2009 - 2010
- Prospective Validation of Genomic Signatures of Chemosensitivity in NSCLC awarded by National Institutes of Health 2009 - 2010
- Biomarker Studies for Novel Anti-Cancer Agents awarded by National Institutes of Health 2003 - 2008
- Phase I/II Trial of ZD1839 and Celecoxib in Ex-Smokers awarded by National Institutes of Health 2002 - 2007
- Measurement of Hypoxia in Non-Small Cell Lung Carcinoma awarded by National Institutes of Health 2002 - 2006
- Dexasome Based Immunotherapy of Lung Cancer awarded by National Institutes of Health 2001 - 2004
- Cancer and Leukemia Group B awarded by National Institutes of Health 1998 - 2003
- Cancer and Leukemia Group B awarded by National Institutes of Health 1988 - 2003
- Cancer and Leukemia Group B awarded by National Institutes of Health 1988 - 2003
- Using Plasma TGFB1 Levels to Escalate Radiotherapy Doses awarded by National Institutes of Health 2000 - 2003
- Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
- Comprehensive Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
- Comprehensive Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
- Cancer And Leukemia Group B awarded by National Institutes of Health 1993 - 1998
- Cancer And Leukemia Group B awarded by National Institutes of Health 1988 - 1998
Publications & Artistic Works
Selected Publications
- Book Sections
  - McKinney, MS, and Crawford, J. "Erythropoiesis-stimulating agents in older adults with cancer." In Practical Geriatric Oncology, 338-350. January 1, 2010. Full Text
- Conference Papers
  - Lyman, GH, Crawford, J, Dale, DC, Whittaker, S, and Tomita, D. "Changing Patterns of Chemotherapy Delivery and Supportive Care for Aggressive B-Cell Non-Hodgkin's Lymphoma." November 18, 2011. Link to Item
- Journal Articles
  - Tandberg, DJ, Kelsey, CR, D'Amico, TA, Crawford, J, Chino, JP, Tong, BC, Ready, NE, and Wright, A. "Patterns of Failure After Surgery for Non-Small-cell Lung Cancer Invading the Chest Wall." Clinical lung cancer 18, no. 4 (July 2017): e259-e265. Full Text
  - Riedel, RF, Meadows, KL, Lee, PH, Morse, MA, Uronis, HE, Blobe, GC, George, DJ, Crawford, J, Niedzwiecki, D, Rushing, CN, Arrowood, CC, and Hurwitz, HI. "Phase I study of pazopanib plus TH-302 in advanced solid tumors." Cancer chemotherapy and pharmacology 79, no. 3 (March 2017): 611-619. Full Text
  - Wang, X, Wang, X, Hodgson, L, George, SL, Sargent, DJ, Foster, NR, Ganti, AK, Stinchcombe, TE, Crawford, J, Kratzke, R, Adjei, AA, Kindler, HL, Vokes, EE, and Pang, H. "Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." The oncologist 22, no. 2 (February 10, 2017): 189-198. Full Text
  - Kelley, MJ, Jha, G, Shoemaker, D, Herndon, JE, Gu, L, Barry, WT, Crawford, J, and Ready, N. "Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer." Cancer investigation 35, no. 1 (January 2017): 32-35. Full Text
  - Boyer, MJ, Gu, L, Wang, X, Kelsey, CR, Yoo, DS, Onaitis, MW, Dunphy, FR, Crawford, J, Ready, NE, and Salama, JK. "Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer." Lung cancer (Amsterdam, Netherlands) 98 (August 2016): 76-78. Full Text
  - Crawford, J, Prado, CMM, Johnston, MA, Gralla, RJ, Taylor, RP, Hancock, ML, and Dalton, JT. "Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)." Current oncology reports 18, no. 6 (June 2016): 37-. (Review) Full Text
  - Raftopoulos, H, Laadem, A, Hesketh, PJ, Goldschmidt, J, Gabrail, N, Osborne, C, Ali, M, Sherman, ML, Wang, D, Glaspy, JA, Puccio-Pick, M, Zou, J, and Crawford, J. "Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 24, no. 4 (April 2016): 1517-1525. Full Text
  - Salama, JK, Gu, L, Wang, X, Pang, HH, Bogart, JA, Crawford, J, Schild, SE, Vokes, EE, and Ready, NE. "Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE)." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 11, no. 3 (March 2016): 361-369. Full Text
  - Crawford, J, Wheatley-Price, P, and Feliciano, JL. "Treatment of Lung Cancer in Medically Compromised Patients." American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting 35 (January 2016): e484-e491. Full Text
  - Fearon, K, Argiles, JM, Baracos, VE, Bernabei, R, Coats, A, Crawford, J, Deutz, NE, Doehner, W, Evans, WJ, Ferrucci, L, Garcia, JM, Gralla, RJ, Jatoi, A, Kalantar-Zadeh, K, Lainscak, M, Morley, JE, Muscaritoli, M, Polkey, MI, Rosano, G, Rossi-Fanelli, F, Schols, AM, Strasser, F, Vellas, B, von Haehling, S, and Anker, SD. "Request for regulatory guidance for cancer cachexia intervention trials." Journal of cachexia, sarcopenia and muscle 6, no. 4 (December 2015): 272-274. Full Text Open Access Copy
  - Wang, X, Gu, L, Zhang, Y, Sargent, DJ, Richards, W, Ganti, AK, Crawford, J, Cohen, HJ, Stinchcombe, T, Vokes, E, and Pang, H. "Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups." Lung cancer (Amsterdam, Netherlands) 90, no. 2 (November 2015): 281-287. Full Text
  - Smith, TJ, Bohlke, K, Lyman, GH, Carson, KR, Crawford, J, Cross, SJ, Goldberg, JM, Khatcheressian, JL, Leighl, NB, Perkins, CL, Somlo, G, Wade, JL, Wozniak, AJ, Armitage, JO, and American Society of Clinical Oncology, . "Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33, no. 28 (October 2015): 3199-3212. (Review) Full Text
  - Lyman, GH, Dale, DC, Legg, JC, Abella, E, Morrow, PK, Whittaker, S, and Crawford, J. "Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?." Cancer medicine 4, no. 8 (August 2015): 1153-1160. Full Text
  - Lyman, GH, Reiner, M, Morrow, PK, and Crawford, J. "The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy." Annals of oncology : official journal of the European Society for Medical Oncology 26, no. 7 (July 2015): 1452-1458. Full Text
  - Ready, NE, Pang, HH, Gu, L, Otterson, GA, Thomas, SP, Miller, AA, Baggstrom, M, Masters, GA, Graziano, SL, Crawford, J, Bogart, J, and Vokes, EE. "Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33, no. 15 (May 2015): 1660-1665. Full Text
  - Havrilesky, LJ, Reiner, M, Morrow, PK, Watson, H, and Crawford, J. "A review of relative dose intensity and survival in patients with metastatic solid tumors." Critical reviews in oncology/hematology 93, no. 3 (March 2015): 203-210. (Review) Full Text
  - Pepek, JM, Marks, LB, Berry, MF, Ready, NE, Gee, NG, Coleman, RE, D'Amico, TA, Crawford, J, and Kelsey, CR. "Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy." Practical radiation oncology 5, no. 2 (March 2015): 79-84. Full Text
  - Pepek, JM, Marks, LB, Berry, MF, Ready, NE, Gee, NG, Coleman, RE, D'Amico, TA, Crawford, J, and Kelsey, CR. "Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy." Practical Radiation Oncology 5, no. 2 (March 1, 2015): 79-84. Full Text
  - Culakova, E, Poniewierski, MS, Wolff, DA, Dale, DC, Crawford, J, and Lyman, GH. "The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study." SpringerPlus 4 (January 2015): 396-. Full Text
  - Havrilesky, LJ, Reiner, M, Morrow, PK, Watson, H, and Crawford, J. "A review of relative dose intensity and survival in patients with metastatic solid tumors." Critical Reviews in Oncology/Hematology 93, no. 3 (January 1, 2015): 203-210. (Review) Full Text
  - Culakova, E, Poniewierski, MS, Crawford, J, Dale, DC, and Lyman, GH. "Impact of Comorbidities on Length of Stay and Mortality in Hospitalized Patients with Cancer and Febrile Neutropenia." BLOOD 124, no. 21 (December 6, 2014). Link to Item
  - Xu, H, Kaye, JA, Saltus, CW, Crawford, J, Gasal, E, and Goodnough, LT. "Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents." Expert review of hematology 7, no. 5 (October 2014): 617-633. (Review) Full Text
  - Stevenson, M, Christensen, J, Shoemaker, D, Foster, T, Barry, WT, Tong, BC, Wahidi, M, Shofer, S, Datto, M, Ginsburg, G, Crawford, J, D'Amico, T, and Ready, N. "Tumor acquisition for biomarker research in lung cancer." Cancer investigation 32, no. 6 (July 2014): 291-298. Full Text
  - Crawford, J, and Rodgers, GM. "Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?." Journal of the National Comprehensive Cancer Network : JNCCN 12, no. 5 Suppl (May 2014): 821-824. Full Text
  - Culakova, E, Thota, R, Poniewierski, MS, Kuderer, NM, Wogu, AF, Dale, DC, Crawford, J, and Lyman, GH. "Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study." Cancer medicine 3, no. 2 (April 2014): 434-444. Full Text
  - Crawford, J, Swanson, P, Schwarzenberger, P, Sandler, A, Prager, D, Zhang, K, Freeman, DJ, Johnson, CW, Krishnan, K, and Johnson, D. "A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer." JOURNAL OF THORACIC ONCOLOGY 8, no. 12 (December 2013): 1510-1518. Full Text Link to Item
  - Salama, JK, Pang, H, Bogart, JA, Blackstock, AW, Urbanic, JJ, Hodgson, L, Crawford, J, and Vokes, EE. "Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70Gy daily radiotherapy: CALGB 30904." Lung Cancer 82, no. 3 (December 1, 2013): 436-440. Full Text
  - Ramalingam, S, Crawford, J, Chang, A, Manegold, C, Perez-Soler, R, Douillard, J-Y, Thatcher, N, Barlesi, F, Owonikoko, T, Wang, Y, Pultar, P, Zhu, J, Malik, R, Giaccone, G, and Investigators, FORTIS-MS. "Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)." ANNALS OF ONCOLOGY 24, no. 11 (November 2013): 2875-2880. Full Text Link to Item
  - Crawford, J, Armitage, J, Balducci, L, Becker, PS, Blayney, DW, Cataland, SR, Heaney, ML, Hudock, S, Kloth, DD, Kuter, DJ, Lyman, GH, McMahon, B, Rugo, HS, Saad, AA, Schwartzberg, LS, Shayani, S, Steensma, DP, Talbott, M, Vadhan-Raj, S, Westervelt, P, Westmoreland, M, Dwyer, M, and Ho, M. "Myeloid Growth Factors." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 11, no. 10 (October 2013): 1266-1290. Link to Item
  - Crawford, J. "Moving Forward With Myeloid Growth Factors." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 11, no. 10 (October 2013): 1181-1182. Link to Item
  - Lyman, GH, Dale, DC, Culakova, E, Poniewierski, MS, Wolff, DA, Kuderer, NM, Huang, M, and Crawford, J. "The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials." Ann Oncol 24, no. 10 (October 2013): 2475-2484. (Review) Full Text Link to Item
  - Crawford, J, and Barth Geller, G. "Prevention and treatment of chemotherapy-induced neutropenia." Clinical Advances in Hematology and Oncology 11, no. 8 (August 1, 2013): 514-517.
  - Salama, JK, Hodgson, L, Pang, H, Urbanic, JJ, Blackstock, AW, Schild, SE, Crawford, J, Bogart, JA, Vokes, EE, and Cancer and Leukemia Group B, . "A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904." J Thorac Oncol 8, no. 8 (August 2013): 1043-1049. Full Text Link to Item
  - Lyman, GH, Dale, DC, Tomita, D, Whittaker, S, and Crawford, J. "A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting." Breast Cancer Res Treat 139, no. 3 (June 2013): 863-872. Full Text Link to Item
  - Hanna, RK, Poniewierski, MS, Laskey, RA, Lopez, MA, Shafer, A, Van Le, L, Crawford, J, Dale, DC, Gehrig, PA, Secord, AA, Havrilesky, LJ, and Lyman, GH. "Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer." Gynecol Oncol 129, no. 1 (April 2013): 74-80. Full Text Link to Item
  - Lyman, GH, Dale, DC, Tomita, D, Whittaker, S, and Crawford, J. "A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting." Breast Cancer Research and Treatment 139, no. 3 (2013): 863-872. Full Text
  - Mauguen, A, Pignon, J-P, Burdett, S, Domerg, C, Fisher, D, Paulus, R, Mandrekar, SJ, Belani, CP, Shepherd, FA, Eisen, T, Pang, H, Collette, L, Sause, WT, Dahlberg, SE, Crawford, J, O'Brien, M, Schild, SE, Parmar, M, Tierney, JF, Pechoux, CL, and Michiels, S. "Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-analysis of meta-analyses of individual patients' data." The Lancet Oncology 14, no. 7 (2013): 619-626. Full Text
  - Mauguen, A, Pignon, J-P, Burdett, S, Domerg, C, Fisher, D, Paulus, R, Mandrekar, SJ, Belani, CP, Shepherd, FA, Eisen, T, and al, E. "Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data." The Lancet Oncology (2013). Full Text
  - Salama, JK, Hodgson, L, Pang, H, Urbanic, JJ, Blackstock, AW, Schild, SE, Crawford, J, Bogart, JA, and Vokes, EE. "A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904." Journal of Thoracic Oncology 8, no. 8 (2013): 1043-1049. Full Text
  - Salama, JK, Pang, H, Bogart, JA, Blackstock, AW, Urbanic, JJ, Hodgson, L, Crawford, J, and Vokes, EE. "Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904." Lung Cancer (2013).
  - Shayne, M, Culakova, E, Poniewierski, MS, Dale, DC, Crawford, J, Wogu, AF, and Lyman, GH. "Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies." Journal of Geriatric Oncology (2013). Full Text
  - Shayne, M, Culakova, E, Poniewierski, MS, Dale, DC, Crawford, J, Wogu, AF, and Lyman, GH. "Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies." Journal of Geriatric Oncology 4, no. 4 (2013): 310-318. Full Text
  - Brodowicz, T, Ciuleanu, T, Crawford, J, Filipits, M, Fischer, JR, Georgoulias, V, Gridelli, C, Hirsch, FR, Jassem, J, Kosmidis, P, Krzakowski, M, Manegold, C, Pujol, JL, Stahel, R, Thatcher, N, Vansteenkiste, J, Minichsdorfer, C, Zöchbauer-Müller, S, Pirker, R, and Zielinski, CC. "Third CECOG consensus on the systemic treatment of non-small-cell lung cancer." Annals of Oncology 23, no. 5 (2012): 1223-1229. Full Text
  - Chan, A, Verma, S, Loibl, S, Crawford, J, Choi, MR, Dreiling, L, and Vandenberg, T. "Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors." Critical Reviews in Oncology/Hematology 81, no. 2 (2012): 136-150. Full Text
  - Gaspar, LE, McNamara, EJ, Gay, EG, Putnam, JB, Crawford, J, Herbst, RS, and Bonner, JA. "Small-cell lung cancer: Prognostic factors and changing treatment over 15 years." Clinical Lung Cancer 13, no. 2 (2012): 115-122. Full Text
  - Jänne, PA, Wang, X, Socinski, MA, Crawford, J, Stinchcombe, TE, Gu, L, Capelletti, M, Edelman, MJ, Villalona-Calero, MA, Kratzke, R, Vokes, EE, and Miller, VA. "Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial." Journal of Clinical Oncology 30, no. 17 (2012): 2063-2069. Full Text
  - Vansteenkiste, J, Glaspy, J, Henry, D, Ludwig, H, Pirker, R, Tomita, D, Collins, H, and Crawford, J. "Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses." Lung Cancer 76, no. 3 (2012): 478-485. Full Text
  - Salama, JK, Stinchcombe, TE, Gu, L, Wang, X, Morano, K, Bogart, JA, Crawford, JC, Socinski, MA, Blackstock, AW, Vokes, EE, and Cancer and Leukemia Group B, . "Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105." Int J Radiat Oncol Biol Phys 81, no. 4 (November 15, 2011): e269-e274. Full Text Link to Item
  - Zeliadt, SB, Sekaran, NK, Hu, EY, Slatore, CC, Au, DH, Backhus, L, Wu, DY, Crawford, J, Lyman, GH, and Dale, DC. "Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest." J Thorac Oncol 6, no. 10 (October 2011): 1726-1732. Full Text Link to Item
  - Crawford, J, Allen, J, Armitage, J, Blayney, DW, Cataland, SR, Heaney, ML, Htoy, S, Hudock, S, Kloth, DD, Kuter, DJ, Lyman, GH, McMahon, B, Steensma, DP, Vadhan-Raj, S, Westervelt, P, Westmoreland, M, and National Comprehensive Cancer Network, . "Myeloid growth factors." J Natl Compr Canc Netw 9, no. 8 (August 1, 2011): 914-932. Link to Item
  - Lyman, GH, Kuderer, NM, Crawford, J, Wolff, DA, Culakova, E, Poniewierski, MS, and Dale, DC. "Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy." Cancer 117, no. 9 (May 1, 2011): 1917-1927. Full Text Link to Item
  - Krug, LM, Crawford, J, Ettinger, DS, Shapiro, GI, Spigel, D, Reiman, T, Temel, JS, Michelson, GC, Young, DY, Hoch, U, and Adelman, DC. "Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer." Journal of Thoracic Oncology 6, no. 2 (2011): 384-386. Full Text
  - Dubey, S, Jänne, PA, Krug, L, Pang, H, Wang, X, Heinze, R, Watt, C, Crawford, J, Kratzke, R, Vokes, E, and Kindler, HL. "A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307." J Thorac Oncol 5, no. 10 (October 2010): 1655-1661. Full Text Link to Item
  - Lyman, GH, Dale, DC, Wolff, DA, Culakova, E, Poniewierski, MS, Kuderer, NM, and Crawford, J. "Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review." J Clin Oncol 28, no. 17 (June 10, 2010): 2914-2924. (Review) Full Text Link to Item
  - Crawford, J, Caserta, C, Roila, F, and ESMO Guidelines Working Group, . "Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications." Ann Oncol 21 Suppl 5 (May 2010): v248-v251. Full Text Link to Item
  - Jones, LW, Eves, ND, Kraus, WE, Potti, A, Crawford, J, Blumenthal, JA, Peterson, BL, and Douglas, PS. "The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design. (Published online)" BMC Cancer 10 (April 21, 2010): 155-. Full Text Open Access Copy Link to Item
  - Mostertz, W, Stevenson, M, Acharya, C, Chan, I, Walters, K, Lamlertthon, W, Barry, W, Crawford, J, Nevins, J, and Potti, A. "Age- and sex-specific genomic profiles in non-small cell lung cancer." JAMA 303, no. 6 (February 10, 2010): 535-543. Full Text Link to Item
  - Zagar, TM, Blackwell, S, Crawford, J, D'Amico, T, Christensen, JD, Sporn, TA, and Kelsey, CR. "Preoperative radiation therapy and chemotherapy for pulmonary blastoma: a case report." J Thorac Oncol 5, no. 2 (February 2010): 282-283. Full Text Link to Item
  - Aapro, M, Crawford, J, and Kamioner, D. "Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: Where are we now?." Supportive Care in Cancer 18, no. 5 (2010): 529-541. Full Text
  - Glaspy, J, Crawford, J, Vansteenkiste, J, Henry, D, Rao, S, Bowers, P, Berlin, JA, Tomita, D, Bridges, K, and Ludwig, H. "Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes." British Journal of Cancer 102, no. 2 (2010): 301-315. Full Text
  - Kuderer, NM, Dale, DC, Crawford, J, and Lyman, GH. "Reply to N. Lathia et al." Journal of Clinical Oncology 28, no. 36 (2010): e764-. Full Text
  - Stevenson, M, Mostertz, W, Acharya, C, Kim, W, Walters, K, Barry, W, Higgins, K, Tuchman, SA, Crawford, J, Vlahovic, G, Ready, N, Onaitis, M, and Potti, A. "Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma." Clin Cancer Res 15, no. 24 (December 15, 2009): 7553-7561. Full Text Link to Item
  - Shayne, M, Culakova, E, Wolff, D, Poniewierski, MS, Dale, DC, Crawford, J, and Lyman, GH. "Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy." Cancer 115, no. 22 (November 15, 2009): 5319-5328. Full Text Link to Item
  - Crawford, J, Caserta, C, Roila, F, and ESMO Guidelines Working Group, . "Hematopoietic growth factors: ESMO recommendations for the applications." Ann Oncol 20 Suppl 4 (May 2009): 162-165. (Review) Full Text Link to Item
  - Brouwers, M, Oliver, TK, Crawford, J, Ellison, P, Evans, WK, Gagliardi, A, Lacourciere, J, Lo, D, Mai, V, McNair, S, Minuk, T, Rabeneck, L, Rand, C, Ross, J, Smylie, J, Srigley, J, Stern, H, and Trudeau, M. "Cancer diagnostic assessment programs: Standards for the organization of care in Ontario." Current Oncology 16, no. 6 (2009): 29-41.
  - Crawford, J, Armitage, J, Balducci, L, Bennett, C, Blayney, DW, Cataland, SR, Dale, DC, Demetri, GD, Erba, HP, Foran, J, Freifeld, AG, Goemann, M, Heaney, ML, Htoy, S, Hudock, S, Kloth, DD, Kuter, DJ, Lyman, GH, Michaud, LB, Miyata, SC, Tallman, MS, Vadhan-Raj, S, Westervelt, P, Wong, MK, and National Comprehensive Cancer Network, . "Myeloid growth factors." J Natl Compr Canc Netw 7, no. 1 (January 2009): 64-83. Link to Item
  - Gerena-Lewis, M, Crawford, J, Bonomi, P, Maddox, AM, Hainsworth, J, McCune, DE, Shukla, R, Zeigler, H, Hurtubise, P, Chowdhury, TR, Fletcher, B, Dyehouse, K, Ghalie, R, and Jazieh, AR. "A phase II trial of denileukin diftitox in patients with previously treated advanced non-small cell lung cancer." American Journal of Clinical Oncology: Cancer Clinical Trials 32, no. 3 (2009): 269-273. Full Text
  - Ludwig, H, Crawford, J, Österborg, A, Vansteenkiste, J, Henry, DH, Fleishman, A, Bridges, K, and Glaspy, JA. "Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia." Journal of Clinical Oncology 27, no. 17 (2009): 2838-2847. Full Text
  - Stephenson, JJ, Gregory, C, Burris, H, Larson, T, Verma, U, Cohn, A, Crawford, J, Cohen, RB, Martin, J, Lum, P, Yang, X, and Amado, RG. "An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors." Clinical Colorectal Cancer 8, no. 1 (2009): 29-37. Full Text
  - Jones, LW, Eves, ND, Peterson, BL, Garst, J, Crawford, J, West, MJ, Mabe, S, Harpole, D, Kraus, WE, and Douglas, PS. "Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study." Cancer 113, no. 12 (December 15, 2008): 3430-3439. Full Text Link to Item
  - Meyer, J, Wahidi, M, Shofer, S, Evans, J, Crawford, J, and Kelsey, CR. "Formation of a bronchoesophageal fistula following concurrent radiation and chemotherapy for lung cancer in the setting of Behçet's disease." J Thorac Oncol 3, no. 11 (November 2008): 1361-1362. (Letter) Full Text Link to Item
  - Crawford, J, Dale, DC, Kuderer, NM, Culakova, E, Poniewierski, MS, Wolff, D, and Lyman, GH. "Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice." J Natl Compr Canc Netw 6, no. 2 (February 2008): 109-118. Link to Item
  - Greco, FA, Bonomi, P, Crawford, J, Kelly, K, Oh, Y, Halpern, W, Lo, L, Gallant, G, and Klein, J. "Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer." Lung Cancer 61, no. 1 (2008): 82-90. Full Text
  - Weiner, LM, Belldegrun, AS, Crawford, J, Tolcher, AW, Lockbaum, P, Arends, RH, Navale, L, Amado, RG, Schwab, G, and Figlin, RA. "Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies." Clinical Cancer Research 14, no. 2 (2008): 502-508. Full Text
  - Shayne, M, Culakova, E, Poniewierski, MS, Wolff, D, Dale, DC, Crawford, J, and Lyman, GH. "Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy." Cancer 110, no. 7 (October 1, 2007): 1611-1620. Full Text Link to Item
  - Crawford, J. "Hitting our stride." Support Cancer Ther 4, no. 4 (September 1, 2007): 178-179. Full Text Link to Item
  - Kuderer, NM, Dale, DC, Crawford, J, and Lyman, GH. "Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review." J Clin Oncol 25, no. 21 (July 20, 2007): 3158-3167. (Review) Full Text Link to Item
  - Griggs, JJ, Culakova, E, Sorbero, MES, Poniewierski, MS, Wolff, DA, Crawford, J, Dale, DC, and Lyman, GH. "Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens." J Clin Oncol 25, no. 18 (June 20, 2007): 2522-2527. Full Text Link to Item
  - Riedel, RF, Andrews, C, Garst, J, Dunphy, F, Herndon, JE, Blackwell, S, Barbour, S, and Crawford, J. "A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer." J Thorac Oncol 2, no. 6 (June 2007): 520-525. Full Text Link to Item
  - Crawford, J. "May day." Support Cancer Ther 4, no. 3 (May 1, 2007): 135-136. Full Text Link to Item
  - Crawford, J, Robert, F, Perry, MC, Belani, C, Williams, D, and Anemia Prevention in NSCLC Group, . "A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy." J Thorac Oncol 2, no. 3 (March 2007): 210-220. Full Text Link to Item
  - Crawford, J, Althaus, B, Armitage, J, Balducci, L, Bennett, C, Blayney, DW, Cataland, SR, Dale, DC, Demetri, GD, Erba, HP, Foran, J, Freifeld, AG, Heaney, ML, Htoy, S, Kloth, DD, Lyman, GH, Messersmith, WA, Michaud, LB, Miyata, SC, Robbins, A, Tallman, MS, Vadhan-Raj, S, Westervelt, P, Wong, MK, and National Comprehensive Cancer Network (NCCN), . "Myeloid growth factors. Clinical practice guidelines in oncology." J Natl Compr Canc Netw 5, no. 2 (February 2007): 188-202. Link to Item
  - Griggs, JJ, Culakova, E, Sorbero, MES, van Ryn, M, Poniewierski, MS, Wolff, DA, Crawford, J, Dale, DC, and Lyman, GH. "Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy." J Clin Oncol 25, no. 3 (January 20, 2007): 277-284. Full Text Link to Item
  - Cosler, LE, Eldar-Lissai, A, Culakova, E, Kuderer, NM, Dale, D, Crawford, J, and Lyman, GH. "Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective." Pharmacoeconomics 25, no. 4 (2007): 343-351. Link to Item
  - Crawford, J. "Erythropoietin: High profile, high scrutiny." Journal of Clinical Oncology 25, no. 9 (2007): 1021-1023. Full Text
  - Crawford, J. "Update on neutropenia and myeloid growth factors." Journal of Supportive Oncology 5, no. 4 SUPPL. 2 (2007): 27-29.
  - Crawford, J. "Controlling symptoms in elderly lung cancer patients." Journal of Supportive Oncology 5, no. 2 (2007): 78-79.
  - Crawford, J. "Cancer management in the era of targeted agents." Support Cancer Ther 4, no. 2 (January 1, 2007): 69-. Full Text Link to Item
  - Reddy, GK, Shivakumar, L, Muneer, S, and Crawford, J. "A phase II study of eltrombopag in the treatment of thrombocytopenia in patients with relapsed/refractory idiopathic thrombocytopenic purpura." Supportive Cancer Therapy 4, no. 2 (2007): 73-74.
  - Reddy, GK, Shivakumar, L, Muneer, S, and Crawford, J. "Long-term analysis of the safety and tolerability of the oral iron chelator deferasirox in patients with transfusional iron overload." Supportive Cancer Therapy 4, no. 2 (2007): 75-77.
  - Reddy, GK, Shivakumar, L, Muneer, S, and Crawford, J. "Preliminary results of a phase II dose-finding study of subcutaneous Hematide™ in patients with cancer receiving chemotherapy." Supportive Cancer Therapy 4, no. 2 (2007): 74-75.
  - Reddy, GK, Shivakumar, L, Muneer, S, and Crawford, J. "Long-term effects of the novel thrombopoietic agent AMG-531 in patients with immune thrombocytopenic purpura." Supportive Cancer Therapy 4, no. 2 (2007): 72-73.
  - Riedel, RF, Crawford, J, Dunphy, F, Herndon, JE, Garst, J, and Kelley, MJ. "Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer." Lung Cancer 54, no. 3 (December 2006): 431-432. (Letter) Full Text Link to Item
  - Shayne, M, Crawford, J, Dale, DC, Culakova, E, Lyman, GH, and ANC Study Group, . "Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy." Breast Cancer Res Treat 100, no. 3 (December 2006): 255-262. Full Text Link to Item
  - Aapro, MS, Cameron, DA, Pettengell, R, Bohlius, J, Crawford, J, Ellis, M, Kearney, N, Lyman, GH, Tjan-Heijnen, VC, Walewski, J, Weber, DC, Zielinski, C, and European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party, . "EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours." Eur J Cancer 42, no. 15 (October 2006): 2433-2453. (Review) Full Text Link to Item
  - Anscher, MS, Garst, J, Marks, LB, Larrier, N, Dunphy, F, Herndon, JE, Clough, R, Marino, C, Vujaskovic, Z, Zhou, S, Dewhirst, MW, Shafman, TD, and Crawford, J. "Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury." Int J Radiat Oncol Biol Phys 66, no. 2 (October 1, 2006): 477-482. Full Text Link to Item
  - Crawford, J. "Disease management and patient-reported outcomes." Support Cancer Ther 4, no. 1 (October 1, 2006): 14-. Full Text Link to Item
  - Crawford, J, Kosmidis, PA, Hirsch, FR, and Langer, CJ. "Targeting anemia in patients with lung cancer." J Thorac Oncol 1, no. 7 (September 2006): 716-725. (Review) Link to Item
  - Crawford, J. "Erythropoiesis-stimulating protein support and survival." Oncology (Williston Park) 20, no. 8 Suppl 6 (July 2006): 39-43. (Review) Link to Item
  - Smith, TJ, Khatcheressian, J, Lyman, GH, Ozer, H, Armitage, JO, Balducci, L, Bennett, CL, Cantor, SB, Crawford, J, Cross, SJ, Demetri, G, Desch, CE, Pizzo, PA, Schiffer, CA, Schwartzberg, L, Somerfield, MR, Somlo, G, Wade, JC, Wade, JL, Winn, RJ, Wozniak, AJ, and Wolff, AC. "2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline." J Clin Oncol 24, no. 19 (July 1, 2006): 3187-3205. Full Text Link to Item
  - Kuderer, NM, Dale, DC, Crawford, J, Cosler, LE, and Lyman, GH. "Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients." Cancer 106, no. 10 (May 15, 2006): 2258-2266. Full Text Link to Item
  - Crawford, J. "Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia." Oncology (Williston Park) 20, no. 5 Suppl 4 (April 2006): 22-28. (Review) Link to Item
  - Crawford, J. "Colony-stimulating factor use in the context of refined risk and benefit assessments." Oncology (Williston Park) 20, no. 5 Suppl 4 (April 2006): 9-10. Link to Item
  - Crawford, J. "Becoming a supportive cancer therapy generalist." Support Cancer Ther 3, no. 3 (April 1, 2006): 134-. Full Text Link to Item
  - Daniel, D, and Crawford, J. "Myelotoxicity from chemotherapy." Semin Oncol 33, no. 1 (February 2006): 74-85. (Review) Full Text Link to Item
  - Crawford, J. "Integrating support into cancer therapy." Support Cancer Ther 3, no. 2 (January 1, 2006): 71-72. Full Text Link to Item
  - Fanucchi, MP, Fossella, FV, Belt, R, Natale, R, Fidias, P, Carbone, DP, Govindan, R, Raez, LE, Robert, F, Ribeiro, M, Akerley, W, Kelly, K, Limentani, SA, Crawford, J, Reimers, H-J, Axelrod, R, Kashala, O, Sheng, S, and Schiller, JH. "Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer." Journal of Clinical Oncology 24, no. 31 (2006): 5025-5033. Full Text
  - Garst, J, Herndon, JE, Shafman, T, Campagna, L, Blackwell, S, Padilla, K, Bjurstrom, T, Andrews, C, Maravich-May, D, Anderson, E, and Crawford, J. "A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer." Clin Drug Investig 26, no. 5 (2006): 257-266. Link to Item
  - Johnson, BE, Crawford, J, Downey, RJ, Ettinger, DS, Fossella, F, Grecula, JC, Jahan, T, Kalemkerian, GP, Kessinger, A, Koczywas, M, Langer, CJ, Martins, R, Marymont, MH, Niell, HB, Ramnath, N, Robert, F, and Jr, CCW. "Small cell lung cancer: Clinical Practice Guidelines in Oncology™." JNCCN Journal of the National Comprehensive Cancer Network 4, no. 6 (2006): 602-622.
  - Reddy, GK, Crawford, J, and Jain, VK. "The role of Plerixafor (AMD3100) in mobilizing hematopoietic progenitor cells in patients with hematologic malignancies." Supportive Cancer Therapy 3, no. 2 (2006): 73-76.
  - Daniel, DB, Crawford, J, and National Comprehensive Cancer Network, . "Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy." Curr Hematol Rep 4, no. 6 (November 2005): 441-445. (Review) Link to Item
  - Lamont, EB, Herndon, JE, Weeks, JC, Henderson, IC, Lilenbaum, R, Schilsky, RL, and Christakis, NA. "Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants." J Natl Cancer Inst 97, no. 14 (July 20, 2005): 1080-1083. Full Text Link to Item
  - Crawford, J, Althaus, B, Armitage, J, Blayney, DW, Cataland, S, Dale, DC, Demetri, GD, Foran, J, Heaney, ML, Htoy, S, Kloth, DD, Lyman, GH, Michaud, L, Motl, S, Vadhan-Raj, S, Wong, MK, and National Comprehensive Cancer Network, . "Myeloid growth factors clinical practice guidelines in oncology." J Natl Compr Canc Netw 3, no. 4 (July 2005): 540-555. Link to Item
  - Cosler, LE, Sivasubramaniam, V, Agboola, O, Crawford, J, Dale, D, and Lyman, GH. "Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy." Value Health 8, no. 1 (January 2005): 47-52. Full Text Link to Item
  - Crawford, J, Wolff, D, Culakova, E, Poniewierski, MS, Selby, C, Dale, D, and Lyman, GH. "First-cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: Results from a prospective nationwide study." Journal of Supportive Oncology 3, no. 2 SUPPL. 1 (2005): 52-53.
  - Garst, J, Buller, R, Lane, S, and Crawford, J. "Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer." Clinical Lung Cancer 7, no. 3 (2005): 190-196.
  - Gaspar, LE, Gay, EG, Crawford, J, Putnam, JB, Herbst, RS, and Bonner, JA. "Limited-stage small-cell lung cancer (stages I-III): Observations from the National Cancer Data Base." Clinical Lung Cancer 6, no. 6 (2005): 355-360.
  - Leighl, NB, Paz-Ares, L, Douillard, J-Y, Peschel, C, Arnold, A, Depierre, A, Santoro, A, Betticher, DC, Gatzemeier, U, Jassem, J, Crawford, J, Tu, D, Bezjak, A, Humphrey, JS, Voi, M, Galbraith, S, Hann, K, Seymour, L, and Shepherd, FA. "Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR. 18." Journal of Clinical Oncology 23, no. 12 (2005): 2831-2839. Full Text
  - Miller, KL, Shafman, TD, Anscher, MS, Zhou, S-M, Clough, RW, Garst, JL, Crawford, J, Rosenman, J, Socinski, MA, Blackstock, W, Sibley, GS, and Marks, LB. "Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?." Int J Radiat Oncol Biol Phys 61, no. 1 (January 1, 2005): 64-69. Full Text Link to Item
  - Vokes, EE, Crawford, J, Bogart, J, Socinski, MA, Clamon, G, and Green, MR. "Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer." Clinical cancer research : an official journal of the American Association for Cancer Research 11, no. 13 Pt 2 (2005): 5045s-5050s.
  - Wolff, D, Culakova, E, Poniewierski, MS, Lyman, GH, Dale, DC, and Crawford, J. "Predictors of chemotherapy-induced neutropenia and its complications: Results from a prospective nationwide registry." Journal of Supportive Oncology 3, no. 6 SUPPL. 4 (2005): 24-25.
  - Wolff, DA, Crawford, J, Dale, DC, Poniewierski, MS, and Lyman, GH. "Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systemic chemotherapy." Journal of Supportive Oncology 3, no. 2 SUPPL. 1 (2005): 56-57.
  - Zielinski, CC, Krainer, M, Pirker, R, Tomek, S, Zöchbauer-Müller, S, Beinert, T, Crawford, J, Fischer, JR, Georgoulias, V, Gridelli, C, Hirsch, F, Jassem, J, Herold, C, Kosmidis, P, Krzakowski, M, Manegold, C, Pujol, JL, Thatcher, N, Zandwijk, NV, and Zwitter, M. "Consensus on medical treatment of non-small-cell lung cancer - Update 2004." Lung Cancer 50, no. 1 (2005): 129-137. Full Text
  - Crawford, J. "The importance of chemotherapy dose intensity in lung cancer." Semin Oncol 31, no. 6 Suppl 15 (December 2004): 25-31. (Review) Full Text Link to Item
  - Lyman, GH, Dale, DC, Friedberg, J, Crawford, J, and Fisher, RI. "Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study." J Clin Oncol 22, no. 21 (November 1, 2004): 4302-4311. Full Text Link to Item
  - Marks, LB, Garst, J, Socinski, MA, Sibley, G, Blackstock, AW, Herndon, JE, Zhou, S, Shafman, T, Tisch, A, Clough, R, Yu, X, Turrisi, A, Anscher, M, Crawford, J, Rosenman, J, and Carolina Conformal Therapy Consortium, . "Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium." J Clin Oncol 22, no. 21 (November 1, 2004): 4329-4340. Full Text Link to Item
  - Socinski, MA, Zhang, C, Herndon, JE, Dillman, RO, Clamon, G, Vokes, E, Akerley, W, Crawford, J, Perry, MC, Seagren, SL, and Green, MR. "Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity." Ann Oncol 15, no. 7 (July 2004): 1033-1041. Full Text Link to Item
  - Rocha Lima, CM, Rizvi, NA, Zhang, C, Herndon, JE, Crawford, J, Govindan, R, King, GW, Green, MR, and Cancer Leukemia Group B, . "Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC." Ann Oncol 15, no. 3 (March 2004): 410-418. (Review) Link to Item
  - Crawford, J, Dale, DC, and Lyman, GH. "Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management." Cancer 100, no. 2 (January 15, 2004): 228-237. (Review) Full Text Link to Item
  - Crawford, J, Dale, DC, and Lyman, GH. "Erratum: Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management (Cancer (2004) 100 (228-237))." Cancer 100, no. 9 (2004): 1993-1994.
  - Crawford, J. "Improving the management of chemotherapy-induced neutropenia." Journal of Supportive Oncology 2, no. 2 SUPPL. (2004): 36-39.
  - Foon, KA, Yang, X-D, Weiner, LM, Belldegrun, AS, Figlin, RA, Crawford, J, Rowinsky, EK, Dutcher, JP, Vogelzang, NJ, Gollub, J, Thompson, JA, Schwartz, G, Bukowski, RM, Roskos, LK, and Schwab, GM. "Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody." International Journal of Radiation Oncology Biology Physics 58, no. 3 (2004): 984-990. Full Text
  - Lyman, GH, Dale, DC, and Crawford, J. "Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices." J Clin Oncol 21, no. 24 (December 15, 2003): 4524-4531. Full Text Link to Item
  - Lyman, GH, Morrison, VA, Dale, DC, Crawford, J, Delgado, DJ, Fridman, M, OPPS Working Group, , and ANC Study Group, . "Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy." Leuk Lymphoma 44, no. 12 (December 2003): 2069-2076. Link to Item
  - Riedel, RF, and Crawford, J. "Small-cell lung cancer: a review of clinical trials." Semin Thorac Cardiovasc Surg 15, no. 4 (October 2003): 448-456. (Review) Link to Item
  - Anscher, MS, Marks, LB, Shafman, TD, Clough, R, Huang, H, Tisch, A, Munley, M, Herndon, JE, Garst, J, Crawford, J, and Jirtle, RL. "Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy." Int J Radiat Oncol Biol Phys 56, no. 4 (July 15, 2003): 988-995. Link to Item
  - Dale, DC, McCarter, GC, Crawford, J, and Lyman, GH. "Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials." J Natl Compr Canc Netw 1, no. 3 (July 2003): 440-454. (Review) Link to Item
  - Miller, KL, Marks, LB, Sibley, GS, Clough, RW, Garst, JL, Crawford, J, and Shafman, TD. "Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer." Int J Radiat Oncol Biol Phys 56, no. 2 (June 1, 2003): 355-359. Link to Item
  - Crawford, J. "Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia." Seminars in Oncology 30, no. 4 SUPPL. 13 (2003): 24-30.
  - Crawford, J. "Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy." Pharmacotherapy 23, no. 8 II (2003): 15S-19S.
  - Crawford, J. "New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor." J Natl Compr Canc Netw 1 Suppl 1 (January 2003): S78-S86. (Review) Link to Item
  - Crawford, J. "Pegfilgrastim: The promise of pegylation fulfilled." Annals of Oncology 14, no. 1 (2003): 6-7. Full Text
  - Paridaens, R, Lyman, GH, Leonard, R, Crawford, J, Bosly, A, Constenla, M, Jackisch, C, Pettengell, R, and Szucs, T. "Delivering optimal adjuvant chemotherapy in primary breast cancer: The role of rHuG-CSF." European Journal of Cancer, Supplement 1, no. 9 (2003): 1-12. Full Text
  - Vlahovic, G, and Crawford, J. "Activation of tyrosine kinases in cancer." Oncologist 8, no. 6 (2003): 531-538. (Review) Link to Item
  - Crawford, J. "Anemia and lung cancer." Lung Cancer 38 Suppl 3 (December 2002): S75-S78. (Review) Link to Item
  - Crawford, J. "Neutrophil growth factors." Curr Hematol Rep 1, no. 2 (November 2002): 95-102. (Review) Link to Item
  - Vokes, EE, Herndon, JE, Crawford, J, Leopold, KA, Perry, MC, Miller, AA, and Green, MR. "Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431." J Clin Oncol 20, no. 20 (October 15, 2002): 4191-4198. Full Text Link to Item
  - Crawford, J. "Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence." Oncology (Williston Park) 16, no. 9 Suppl 10 (September 2002): 41-53. (Review) Link to Item
  - Farag, SS, George, SL, Lee, EJ, Baer, M, Dodge, RK, Becknell, B, Fehniger, TA, Silverman, LR, Crawford, J, Bloomfield, CD, Larson, RA, Schiffer, CA, and Caligiuri, MA. "Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420." Clin Cancer Res 8, no. 9 (September 2002): 2812-2819. Link to Item
  - Kornblith, AB, Kemeny, M, Peterson, BL, Wheeler, J, Crawford, J, Bartlett, N, Fleming, G, Graziano, S, Muss, H, Cohen, HJ, and Cancer and Leukemia Group B, . "Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials." Cancer 95, no. 5 (September 1, 2002): 989-996. Full Text Link to Item
  - Crawford, J, Cella, D, Cleeland, CS, Cremieux, P-Y, Demetri, GD, Sarokhan, BJ, Slavin, MB, and Glaspy, JA. "Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy." Cancer 95, no. 4 (August 15, 2002): 888-895. Full Text Link to Item
  - Crawford, J. "Clinical uses of pegylated pharmaceuticals in oncology." Cancer Treat Rev 28 Suppl A (April 2002): 7-11. (Review) Link to Item
  - Crawford, J, Demetri, GD, Gabrilove, JL, Blasi, MV, Sarokhan, BJ, and Glaspy, J. "Clinical benefits of epoetin alfa therapy in patients with lung cancer." Clin Lung Cancer 3, no. 3 (February 2002): 180-190. Link to Item
  - Akehurst, RL, Beinert, T, Crawford, J, Crino, L, Debus, J, Eckersberger, F, Fischer, J, Georgoulias, V, Gridelli, C, Hirsh, FR, Jassem, J, Kosmidis, P, Krainer, M, Krzakowski, M, Manegold, C, Niklinski, J, Pirker, R, Pujol, JL, Scagliotti, G, Thatcher, N, Tomek, S, Tonato, M, Zandwijk, NV, Zielinski, CC, Zöchbauer, S, and Zwitter, M. "Consensus on medical treatment of non-small cell lung cancer." Lung Cancer 38, no. 3 SUPPL. (2002): S3-S7.
  - Crawford, J. "Pegfilgrastim for the prevention of chemotherapy-induced neutropenic complications, with dosing once per chemotherapy cycle." Today's Therapeutic Trends 20, no. 4 (2002): 393-418.
  - Crawford, J. "Clinical benefits of pegylated proteins in oncology." Cancer Treatment Reviews 28, no. SUPPL. A (2002): 1-2. Full Text
  - Crawford, J. "Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia." Drugs 62 Suppl 1 (2002): 89-98. (Review) Link to Item
  - Anscher, MS, Marks, LB, Shafman, TD, Clough, R, Huang, H, Tisch, A, Munley, M, Herndon, JE, Garst, J, Crawford, J, and Jirtle, RL. "Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation." J Clin Oncol 19, no. 17 (September 1, 2001): 3758-3765. Full Text Link to Item
  - Niell, HB, Perry, MC, Clamon, G, Crawford, J, Miller, AA, Herndon, J, and Green, MR. "Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer." Clin Lung Cancer 2, no. 3 (February 2001): 204-209. Link to Item
  - Socinski, MA, Marks, LB, Garst, J, Sibley, GS, Blackstock, W, Turrisi, A, Herndon, J, Zhou, S, Anscher, M, Crawford, J, Shafman, T, and Rosenman, J. "Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium." Oncologist 6 Suppl 1 (2001): 20-24. Link to Item
  - Fossella, FV, DeVore, R, Kerr, RN, Crawford, J, Natale, RR, Dunphy, F, Kalman, L, Miller, V, Lee, JS, Moore, M, Gandara, D, Karp, D, Vokes, E, Kris, M, Kim, Y, Gamza, F, and Hammershaimb, L. "Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group." J Clin Oncol 18, no. 12 (June 2000): 2354-2362. Full Text Link to Item
  - Johnston, E, Crawford, J, Blackwell, S, Bjurstrom, T, Lockbaum, P, Roskos, L, Yang, B-B, Gardner, S, Miller-Messana, MA, Shoemaker, D, Garst, J, and Schwab, G. "Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy." Journal of Clinical Oncology 18, no. 13 (2000): 2522-2528.
  - Ozer, H, Armitage, JO, Bennett, CL, Crawford, J, Demetri, GD, Pizzo, PA, Schiffer, CA, Smith, TJ, Somlo, G, Wade, JC, III, JLW, Winn, RJ, Wozniak, AJ, and Somerfield, MR. "2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines." Journal of Clinical Oncology 18, no. 20 (2000): 3558-3585.
  - Crawford, J, Tomita, DK, Mazanet, R, Glaspy, J, and Ozer, H. "Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy." Cytokines Cell Mol Ther 5, no. 4 (December 1999): 187-193. Link to Item
  - Crawford, J, Foote, M, and Morstyn, G. "Hematopoietic growth factors in cancer chemotherapy." Cancer chemotherapy and biological response modifiers 18 (January 1999): 250-267. (Review)
  - Cremieux, P-Y, Finkelstein, SN, Berndt, ER, Crawford, J, and Slavin, MB. "Cost effectiveness, quality-adjusted life-years and supportive care: Recombinant human erythropoietin as a treatment of cancer-associated anaemia." PharmacoEconomics 16, no. 5 I (1999): 459-472. Full Text
  - DeVore, RF, Johnson, DH, Crawford, J, Garst, J, Dimery, IW, Eckardt, J, Eckhardt, SG, Elfring, GL, Schaaf, LJ, Hanover, CK, and Miller, LL. "Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer." Journal of Clinical Oncology 17, no. 9 (1999): 2710-2720.
  - Johnston, EM, and Crawford, J. "Hematopoietic growth factors in the reduction of chemotherapeutic toxicity." Semin Oncol 25, no. 5 (October 1998): 552-561. (Review) Link to Item
  - Mehdi, SA, Perry, MC, Herndon, JE, Crawford, J, Young, R, and Graziano, SL. "A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer." J Interferon Cytokine Res 18, no. 8 (August 1998): 623-627. Full Text Link to Item
  - Cohen, HJ, Crawford, J, Rao, MK, Pieper, CF, and Currie, MS. "Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly." Am J Med 104, no. 5 (May 1998): 439-444. Link to Item
  - Cohen, HJ, Crawford, J, and Rao, MK. "Erratum: Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly (The American Journal of Medicine (1998) 104 (439-444))." American Journal of Medicine 105, no. 4 (1998): 362--.
  - Crawford, J, and Blackwell, S. "Erythropoietin and the management of anemia in patients with lung cancer." Cancer Control 5, no. 2 SUPPL. (1998): 26-32.
  - III, RD, Johnson, D, Crawford, J, Dimery, I, Eckardt, J, and Eckhardt, SG. "Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer." ONCOLOGY 12, no. 8 SUPPL. (1998): 79-83.
  - Persons, DA, Garst, J, Vollmer, R, and Crawford, J. "Tumor lysis syndrome and acute renal failure after treatment of non- small-cell lung carcinoma with combination irinotecan and cisplatin." American Journal of Clinical Oncology: Cancer Clinical Trials 21, no. 4 (1998): 426-429. Full Text
  - Crawford, J, Kreisman, H, Garewal, H, Jones, SE, Shoemaker, D, Pupa, MR, Armstrong, S, Tomita, D, and Dziem, G. "The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy." Ann Oncol 8, no. 11 (November 1997): 1117-1124. Link to Item
  - Petros, WP, and Crawford, J. "Safety of concomitant use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor with cytotoxic chemotherapy agents." Curr Opin Hematol 4, no. 3 (May 1997): 213-216. (Review) Link to Item
  - Luikart, SD, Herndon, JE, Hollis, DR, MacDonald, M, Maurer, LH, Crawford, J, Clamon, GH, Wright, J, Perry, MC, Ozer, H, and Green, MR. "Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832)." Am J Clin Oncol 20, no. 1 (February 1997): 24-30. Link to Item
  - Crawford, J, Garst, J, and O'Rourke, MA. "Vinorelbine and carboplatin in the treatment of advanced non-small-cell lung cancer." ONCOLOGY 11, no. 10 SUPPL. 12 (1997): 44-48.
  - Crawford, J. "Docetaxel/vinorelbine combination therapy in non-small-cell lung cancer." ONCOLOGY 11, no. 7 SUPPL. (1997): 35-40.
  - Fanucchi, M, Glaspy, J, Crawford, J, Garst, J, Figlin, R, Sheridan, W, Menchaca, D, Tomita, D, Ozer, H, and Harker, L. "Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer." New England Journal of Medicine 336, no. 6 (1997): 404-409. Full Text
  - Neill, HB, Miller, AA, Clamon, GH, Perry, MC, Crawford, J, and Green, MR. "A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer." Seminars in oncology 24, no. 4 Suppl 12 (1997): S12-130-S12-130134-.
  - Niell, HB, Miller, AA, Clamon, GH, Perry, MC, Crawford, J, and Green, MR. "A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer." Seminars in Oncology 24, no. 4 SUPPL.12 (1997): S12130-S12134.
  - Crawford, J, O'Rourke, M, Schiller, JH, Spiridonidis, CH, Yanovich, S, Ozer, H, Langleben, A, Hutchins, L, Koletsky, A, Clamon, G, Burman, S, White, R, and Hohneker, J. "Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer." J Clin Oncol 14, no. 10 (October 1996): 2774-2784. Full Text Link to Item
  - Graziano, SL, Valone, FH, Herndon, JE, Crawford, J, Richards, F, Rege, VB, Clamon, G, and Green, MR. "A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study." Lung Cancer 14, no. 2-3 (June 1996): 315-329. Link to Item
  - Patz, EF, McAdams, HP, Goodman, PC, Blackwell, S, and Crawford, J. "Ambulatory sclerotherapy for malignant pleural effusions." Radiology 199, no. 1 (April 1996): 133-135. Full Text Link to Item
  - Crawford, J, Chang, AY, Gralla, RJ, Souquet, PJ, and Vokes, EE. "Combination regimens and dose intensification in non-small cell lung cancer: A panel discussion (Part I)." Seminars in Oncology 23, no. 2 SUPPL. 5 (1996): 22-24.
  - Crawford, J, Duch, DS, Gralla, RJ, Hillner, BE, Hollen, PJ, and Vokes, EE. "Pharmacoeconomics, quality of life, and combination modalities in non- small cell lung cancer: A panel discussion (Part 2)." Seminars in Oncology 23, no. 2 SUPPL. 5 (1996): 53-55.
  - Crawford, J, and Vokes, EE. "Update on the role of vinorelbine in the treatment of non-small cell lung cancer: Introduction." Seminars in Oncology 23, no. 2 SUPPL. 5 (1996): 1--.
  - Crawford, J. "Update: Vinorelbine (Navelbine) in non-small cell lung cancer." Seminars in Oncology 23, no. 2 SUPPL. 5 (1996): 2-7.
  - Smith, TJ, Ozer, H, Miller, LL, Schiffer, CA, Winn, RJ, Anderson, JR, Anderson, PN, Armitage, JO, Beckhardt, S, Bennett, CL, Bodey, GP, Crawford, J, Davidson, NE, Demetri, GD, Hamm, JT, Hillner, B, Kardinal, CG, Levine, MN, Miller, JA, Ochs, JJ, Santana, VM, Shea, TC, Vadhan-Raj, S, III, JLW, and Weeks, JC. "Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines." Journal of Clinical Oncology 14, no. 6 (1996): 1957-1960.
  - Grichnik, JM, Crawford, J, Jimenez, F, Kurtzberg, J, Buchanan, M, Blackwell, S, Clark, RE, and Hitchcock, MG. "Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients." J Am Acad Dermatol 33, no. 4 (October 1995): 577-583. Link to Item
  - Crawford, J, and George, M. "The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy." Seminars in Oncology 22, no. 3 SUPPL. 7 (1995): 18-22.
  - Deutsch, M, Crawford, J, Leopold, K, Wolfe, W, Foster, W, Herndon, J, Blackwell, S, and Yost, R. "Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer." Cancer 74, no. 4 (August 15, 1994): 1243-1252. Link to Item
  - Brizel, DM, Gockerman, JP, Crawford, J, Hathorn, JW, Moore, JO, Osborne, B, and Prosnitz, LR. "A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease." Cancer 74, no. 1 (July 1, 1994): 159-163. Link to Item
  - Crawford, J, O'Rourke, MA, and Coltman, . "Vinorelbine (Navelbine)/carboplatin combination therapy: Dose intensification with granulocyte colony-stimulating factor." Seminars in Oncology 21, no. 5 SUPPL. 10 (1994): 73-78.
  - Crawford, J, Ozer, H, Stoller, R, Johnson, D, Lyman, G, Tabbara, I, Kris, M, Grous, J, Picozzi, V, Rausch, G, Smith, R, Gradishar, W, Yahanda, A, Vincent, M, Stewart, M, and Glaspy, J. "Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer." Clinical Infectious Diseases 18, no. SUPPL. 2 (1994): S189-S196.
  - Crawford, J. "Vinorelbine (Navelbine) in non-small cell lung cancer: Future directions." Seminars in Oncology 21, no. 5 SUPPL. 10 (1994): 85-88.
  - Hollen, PJ, Gralla, RJ, Kris, MG, Cox, C, Belani, CP, Grunberg, SM, Crawford, J, and Neidhart, JA. "Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: Psychometric assessment of the lung cancer symptom scale." Cancer 73, no. 8 (1994): 2087-2098.
  - Morstyn, G, Brown, S, Gordon, M, Crawford, J, Demetri, G, Rich, W, McGuire, B, Foote, MA, and McNiece, I. "Stem cell factor is a potent synergistic factor in hematopoiesis." Oncology 51, no. 2 (1994): 205-214.
  - Rimer, BK, Herman, D, Crawford, J, and Blackwell, S. "Lung cancer in North Carolina." N C Med J 54, no. 7 (July 1993): 334-340. Link to Item
  - Bowden, M, Crawford, J, Cohen, HJ, and Noyama, O. "A comparative study of monoclonal gammopathies and immunoglobulin levels in Japanese and United States elderly." J Am Geriatr Soc 41, no. 1 (January 1993): 11-14. Link to Item
  - Case, DC, Gerber, MC, Gams, RA, Crawford, J, Votaw, ML, Higano, CS, Pruitt, BT, and Gould, J. "Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma." Leukemia & lymphoma 10 Suppl (January 1993): 73-79. Full Text
  - Deutsch, MA, Leopold, KA, Crawford, J, Wolfe, W, Foster, W, Blackwell, S, and Yost, R. "Carboplatin, etoposide, and radiotherapy, followed by surgery, for the treatment of marginally resectable non-small cell lung cancer." Cancer Treat Rev 19 Suppl C (1993): 53-62. Link to Item
  - Glaspy, JA, Bleecker, G, Crawford, J, Stoller, R, and Strauss, M. "The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy." European Journal of Cancer 29, no. SUPPL. 7 (1993): S23-S30.
  - Johnson, DH, Bass, D, Einhorn, LH, Crawford, J, Perez, CA, Bartolucci, A, Omura, GA, and Greco, FA. "Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: A randomized trial of the southeastern cancer study group." Journal of Clinical Oncology 11, no. 7 (1993): 1223-1229.
  - Jr, DCC, Gerber, MC, Gams, RA, Crawford, J, Votaw, ML, Higano, CS, Pruitt, BT, and Gould, J. "Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma." Leukemia and Lymphoma 10, no. SUPPL. (1993): 73-79.
  - Kavanagh, BD, Montana, GS, Crawford, J, Wolfe, WG, and Anscher, MS. "Long-term results of combined modality therapy for esophageal cancer." Radiation Oncology Investigations 1, no. 4 (1993): 227-234. Full Text
  - Panella, TJ, Smith, DC, Schold, SC, Rogers, MP, Winer, EP, Fine, RL, Crawford, J, Herndon, JE, and Trump, DL. "Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial." Cancer Res 52, no. 9 (May 1, 1992): 2456-2459. Link to Item
  - Roth, BJ, Johnson, DH, Einhorn, LH, Schacter, LP, Cherng, NC, Cohen, HJ, Crawford, J, Randolph, JA, Goodlow, JL, and Broun, GO. "Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group." J Clin Oncol 10, no. 2 (February 1992): 282-291. Full Text Link to Item
  - Blackwell, S, and Crawford, J. "Colony-stimulating factors: Clinical applications." Pharmacotherapy 12, no. 2 II (1992): 20S-31S.
  - Crawford, J, and Green, MR. "The role of colony stimulating factors as an adjunct to lung cancer chemotherapy: A commentary." Lung Cancer 8, no. 3-4 (1992): 153-158.
  - Jr, DCC, Gerber, MC, Gams, RA, Crawford, J, Votaw, ML, Higano, CS, Pruitt, BT, and Gould, J. "Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma." Cancer Research 52, no. 14 (1992): 3871-3874.
  - Kavanagh, B, Anscher, M, Leopold, K, Deutsch, M, Gaydica, E, Dodge, R, Allen, K, Allen, D, Staub, EW, Montana, G, Crawford, J, and Wolfe, W. "Patterns of failure following combined modality therapy for esophageal cancer, 1984-1990." International Journal of Radiation Oncology, Biology, Physics 24, no. 4 (1992): 633-642.
  - Crawford, J, Ozer, H, Stoller, R, Johnson, D, Lyman, G, Tabbara, I, Kris, M, Grous, J, Picozzi, V, and Rausch, G. "Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer." N Engl J Med 325, no. 3 (July 18, 1991): 164-170. Full Text Link to Item
  - Currie, MS, Simel, DL, Christenson, RH, Holmes, C, Crawford, J, Cohen, HJ, and Rao, KM. "Anti-inflammatory effects of pentoxifylline in claudication." Am J Med Sci 301, no. 2 (February 1991): 85-90. Link to Item
  - Stein, RS, Hamm, JT, Higa, GM, Auchter, RM, Crawford, J, and Glaspy, JA. "G-CSF for fever and neutropenia induced by chemotherapy [1]." New England Journal of Medicine 326, no. 4 (1991): 269-270.
  - Brizel, DM, Winer, EP, Prosnitz, LR, Scott, J, Crawford, J, Moore, JO, and Gockerman, JP. "Improved survival in advanced Hodgkin's disease with the use of combined modality therapy." Int J Radiat Oncol Biol Phys 19, no. 3 (September 1990): 535-542. Link to Item
  - Rao, KM, Simel, DL, Cohen, HJ, Crawford, J, and Currie, MS. "Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication." J Lab Clin Med 115, no. 6 (June 1990): 738-744. Link to Item
  - Currie, MS, Vala, M, Pisetsky, DS, Greenberg, CS, Crawford, J, and Cohen, HJ. "Correlation between erythrocyte CR1 reduction and other blood proteinase markers in patients with malignant and inflammatory disorders." Blood 75, no. 8 (April 15, 1990): 1699-1704. Link to Item
  - Currie, MS, Rao, KM, Padmanabhan, J, Jones, A, Crawford, J, and Cohen, HJ. "Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production." J Leukoc Biol 47, no. 3 (March 1990): 244-250. Link to Item
  - Kent, EF, Crawford, J, Cohen, HJ, and Buckley, RH. "Development of multiple monoclonal serum immunoglobulins (multiclonal gammopathy) following both HLA-identical unfractionated and T cell-depleted haploidentical bone marrow transplantation in severe combined immunodeficiency." J Clin Immunol 10, no. 2 (March 1990): 106-114. Link to Item
  - Crawford, J, Oates, S, Wolfe, LA, and Cohen, HJ. "An in vitro analogue of immune dysfunction with altered immunoglobulin production in the aged." J Am Geriatr Soc 37, no. 12 (December 1989): 1140-1146. Link to Item
  - Carter, PW, Cohen, HJ, and Crawford, J. "Hyperviscosity syndrome in association with kappa light chain myeloma." Am J Med 86, no. 5 (May 1989): 591-595. Link to Item
  - Meadows, LM, Rosse, WR, Moore, JO, Crawford, J, Laszlo, J, and Kaufman, RE. "Hodgkin's disease presenting as myelofibrosis." Cancer 64, no. 8 (1989): 1720-1726.
  - Rao, KM, Crawford, J, Currie, MS, and Cohen, HJ. "Actin depolymerization and inhibition of capping induced by pentoxifylline in human lymphocytes and neutrophils." J Cell Physiol 137, no. 3 (December 1988): 577-582. Full Text Link to Item
  - O'Rourke, MA, and Crawford, J. "Lung cancer in the elderly." Compr Ther 14, no. 6 (June 1988): 47-54. (Review) Link to Item
  - Olsen, EA, Crawford, JR, and Vollmer, RT. "Sinus histiocytosis with massive lymphadenopathy. Case report and review of a multisystemic disease with cutaneous infiltrates." J Am Acad Dermatol 18, no. 6 (June 1988): 1322-1332. (Review) Link to Item
  - Simel, DL, DeLong, ER, Feussner, JR, Weinberg, JB, and Crawford, J. "Erythrocyte anisocytosis. Visual inspection of blood films vs automated analysis of red blood cell distribution width." Arch Intern Med 148, no. 4 (April 1988): 822-824. Link to Item
  - Einhorn, LH, Crawford, J, Birch, R, Omura, G, Johnson, DH, and Greco, FA. "Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer." Journal of Clinical Oncology 6, no. 3 (1988): 451-456.
  - O'Rourke, MA, and Crawford, J. "Lung cancer in the elderly." Clin Geriatr Med 3, no. 4 (November 1987): 595-623. (Review) Link to Item
  - Crawford, J, and Cohen, HJ. "Relationship of cancer and aging." Clin Geriatr Med 3, no. 3 (August 1987): 419-432. (Review) Link to Item
  - Eaton, AM, Serota, H, Kernodle, GW, Uglietta, JP, Crawford, J, and Fulkerson, WJ. "Pulmonary hypertension secondary to serum hyperviscosity in a patient with rheumatoid arthritis." Am J Med 82, no. 5 (May 1987): 1039-1045. Link to Item
  - Crawford, J, Eye-Boland, MK, and Cohen, HJ. "Clinical utility of erythrocyte sedimentation rate and plasma protein analysis in the elderly." Am J Med 82, no. 2 (February 1987): 239-246. Link to Item
  - Crawford, J, Eye, MK, and Cohen, HJ. "Evaluation of monoclonal gammopathies in the "well" elderly." Am J Med 82, no. 1 (January 1987): 39-45. Link to Item
  - Sanfilippo, F, Crawford, J, and Ness, G. "Influence of donor-specific blood transfusions on host cellular immune responsiveness." Transplantation Proceedings 18, no. 4 (1986): 692-694.
  - Crawford, J, and Cohen, HJ. "The essential role of L-glutamine in lymphocyte differentiation in vitro." J Cell Physiol 124, no. 2 (August 1985): 275-282. Full Text Link to Item
  - Crawford, J, Cox, EB, and Cohen, HJ. "Evaluation of hyperviscosity in monoclonal gammopathies." Am J Med 79, no. 1 (July 1985): 13-22. Link to Item
  - Crawford, J, and Cohen, HJ. "Aging and neoplasia." Annu Rev Gerontol Geriatr 4 (1984): 3-32. (Review) Link to Item
  - Crawford, J, and Cohen, HJ. "An approach to monoclonal gammopathies in the elderly." Geriatrics 37, no. 10 (October 1982): 97-112. Link to Item
- Other Articles
  - Stevenson, M, Mostertz, W, Acharya, CR, Kim, W, Walters, K, Barry, W, Higgins, K, Tuchman, SA, Crawford, J, Vlahovic, G, Ready, N, Onaitis, M, and Potti, A. "Retraction: characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma." Clin Cancer Res 18, no. 6 (March 15, 2012): 1818-. Full Text Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Grants

Selected Publications

Book Sections

Conference Papers

Journal Articles

Other Articles